195 West Street
About PAREXEL International
THE CLEAREST PATH TO CAREER FULFILLMENT STARTS WITH PAREXEL.
At PAREXEL, the best minds in the industry are simplifying the journey from science to new treatments—and getting them into the hands of those who need them most. If you join us, you can be a part of that. Through innovative processes and technology, your journey with us will not only be challenging but truly rewarding. PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.
PAREXEL Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates approximately 75 locations in over 50 countries around the world, and has more than 15,000 employees. For more information about PAREXEL International, visit www.PAREXEL.com.
488 articles with PAREXEL International
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to market to improve world health, from Clinical through to Commercialization, today announced Gavin Nichols has joined the company as Executive Vice President, Informatics and Information Technology.
EVP and Chief Commercial & Strategy Officer recognized as one of the 100 most inspiring people in life sciences for healthcare industry leadership and patient focus
Strategic Healthcare Consulting subsidiary will support development of global expansion strategies for Asia/Pacific and multinational companies from new Hong Kong presence; biopharma and medtech veteran Gary Cheng to lead local team
Parexel Launches Enhanced Integrated Functional Service Provider Model to Drive Delivery of Innovative Clinical Research Partnerships
Parexel FSP provides biopharmaceutical customers the full spectrum of outsourcing solutions from full service to functional to a hybrid approach across a range of specialized disciplines including Clinical, Data Management, Safety, Regulatory and Medical Affairs
Strategic collaboration leverages CluePoints’ Central Statistical Monitoring (CSM) technology to enhance data quality and reduce operational costs
Collaboration expands Parexel’s capabilities in the region for patient access through China’s native social media channels; enhances ongoing engagement through CLARINESS’s digital patient recruitment portal
There has been a spate of recent news regarding the expansion of facilities and the expected job growth for the biopharma and life sciences industry. Here’s a look at some of those stories.
Parexel Unveils Oncology Center of Excellence to Support Acceleration of Patient-Focused Oncology Drug Development
Parexel International, a leader in supporting the biopharma industry in oncology drug development, unveiled its Oncology Center of Excellence.
PAREXEL Ranked #1 Among Global CROs for Leadership in Phase II/III Clinical Research in Prominent Annual ISR CRO Quality Benchmark Survey
Company recognized for service provider leadership among global customers
3/15/2019Biotech and pharma companies make changes to their executive leadership teams, with moves at Sandoz, PAREXEL, FSD, Karuna, Precision Bio, and more.
Additions support increased demand and complexity in oncology drug development and commercialization
2/15/2019Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.
The new additions join more than 60 former global regulators in the group and will be focused on helping companies understand and work within the current FDA and global regulatory climates to optimize drug development and mitigate risk of unnecessary delays.
Company has once again been recognized for its diverse and flexible workplace by Forbes and FlexJobs.
PAREXEL Introduces New Dedicated Division to Help Emerging Biotech Companies Reach their Goals Quickly and Cost-Effectively
PAREXEL International Corporation today introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.
Recognitions include first-ever Scrip Award for Best Use of Real-World Evidence and “Best in Show” Fierce Innovation Award for partnership with Datavant, as FDA issues framework highlighting potential of RWE to industry
Josef von Rickenbach will step down as Chairman of the Board of Directors effective December 31, 2018.
The program will bring high-value training opportunities to China’s clinical trial sites and investigators, enhancing the execution of local clinical trials and driving innovation in China’s biopharmaceutical industry.
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
Today announced the appointment of new members to the Board of Directors following Pamplona Capital Management’s acquisition in September 2017.